title: Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor.
abstract: BACKGROUND
  Decreased concentrations of the circulating angiogenic factors, free placental growth factor (PLGF) and free vascular endothelial growth factor (VEGF), and increased concentrations of the anti-angiogenic factor, soluble fms-like tyrosine kinase 1 (sFLT-1) have been observed during clinical preeclampsia. We established a new PLGF-ELISA kit for the measurement of PLGF in sera. In the present study, we demonstrated the assay characteristics by measurement of PLGF expression in normal and preeclamptic pregnancies as compared to an established research kit.
  
  
  METHODS
  Blood samples were taken from 64 women with singleton uncomplicated pregnancies for longitudinal measurement of PLGF in the course of pregnancy. In 30 preeclamptic patients, serum levels of PLGF and sFLT-1 were measured by Human PLGF-ELISA and Human sVEGF R1 ELISA according to the described test principles. The assay characteristics of the new PLGF-ELISA were determined and the results were compared to those performed with an available research kit.
  
  
  RESULTS
  The PLGF concentration in normal pregnancies showed a steady increase starting at the beginning of the second trimester with a peak at 28-32 weeks and a consistent decline thereafter. The preeclamptic pregnancies had significant lower serum concentrations of PLGF and significant higher serum concentrations of sFLT-1 as compared to the non-preeclamptic pregnancies. All the measured assay characteristics fulfilled the required specifications. Comparison of the values of the new PLGF-ELISA and the established research kit resulted in a correlation coefficient of 0.921.
  
  
  CONCLUSIONS
  Our results support the hypothesis that an imbalance between factors promoting angiogenesis, such as PLGF, and factors antagonizing angiogenesis, such as sFLT-1, has a fundamental role in the pathogenesis of preeclampsia. The new established ELISA test can be considered reliable and it offers many advantages. As it is authorized for routine diagnostic testing, it may offer new possibilities in the prediction of preeclampsia in clinical routine.
authors.affiliation: Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Schmidt
authors.forename: Canan
authors.initials: C
authors.lastname: Dogan
authors.forename: Cahid
authors.initials: C
authors.lastname: Birdir
authors.forename: Rainer
authors.initials: R
authors.lastname: Callies
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kuhn
authors.forename: Alexandra
authors.initials: A
authors.lastname: Gellhaus
authors.forename: Alfred
authors.initials: A
authors.lastname: Janetzko
authors.forename: Rainer
authors.initials: R
authors.lastname: Kimmig
authors.forename: Sabine
authors.initials: S
authors.lastname: Kasimir-Bauer
mesh_terms: D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000503:physiopathology*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000097:blood*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: C000608036:PGF protein, human; D011257:Pregnancy Proteins; D042461:Vascular Endothelial Growth Factor A; D000072483:Placenta Growth Factor